Plain-English translation of NCT06260891 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing whether zinc gluconate supplements can help strengthen bones in people with sickle cell disease. Researchers will compare two different daily doses of this medication (25 mg and 40 mg) to see which dose works best and is safest. The goal is to understand how the treatment affects bone formation and bone loss in young adults aged 15–40 with this condition.
People with sickle cell disease often develop weak bones and bone loss early in life, putting them at high risk for fractures. Researchers believe that zinc deficiency may be partly responsible for these bone problems, and this study aims to find out whether treating that deficiency with the medication could help prevent or slow bone damage.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either 25 mg or 40 mg of zinc gluconate by mouth once daily. The study is double-blinded, which means neither you nor the research team will know which dose you're receiving—this helps ensure fair results. Researchers will monitor your bone health through blood tests and other measurements to see how your bones respond to the treatment over the study period.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States